Small Cell Lung CancerStatus: open
[17-081 - 1031505-3] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Treatment for Lung Cancer
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. IRB Number 17-081
SponsorsThis trial is sponsored by AbbVie.
Interested in Clinical Trial?
Providers Associated With This Trial
- Moh'd Khushman, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology